Last edition
News about "locally advanced skin cancer"
Sun Pharma's Unloxcyt Gets Preferred NCCN Status
Sun Pharma's UNLOXCYT has received a Category 2A preferred designation in the updated NCCN guidelines for locally advanced Cutaneous Squamous Cell Carcinoma (laCSCC).
Locally Advanced Skin Cancer | 21/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members